Novartis Investigative Site

Dolný Kubín 026 01

0 studies enrolling now · 5 studies all time

What they study most

Cardiovascular Disease and Lipoprotein(a), Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Primary Prevention of Atherosclerotic Cardiovascular Disease

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early